PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF), the health sciences company developing preventative therapies, is moving one step forward to secure its intellectual property, with the retention of a patent law firm.
The Vancouver-based company has hired Australian legal experts Griffith Hack as its patent attorneys to protect its intellectual property and help obtain the necessary patents associated with its therapeutic research and development.
“Following the successful completion of our novel designed peptides derived from Caribbean blue scorpion venom and with our two other programs coming to a close during 2020, we will need to ensure all our intellectual property is patented in order to protect its value,” PreveCeutical said in a statement.
READ: PreveCeutical Medical says it is moving towards proof of concept with its blue scorpion venom research
The firm will be working with Griffith Hack’s Dr Kathryn Morris, a principal and patent attorney, who has qualifications in organic chemistry and intellectual property law.
Specifically, the team is looking to protect its intellectual property developed in its four current research and development programs with UniQuest and the University of Queensland, Australia.
"These patent filings are critical to PreveCeutical as we are now currently working to discuss potential of partnering with biotech and pharmaceutical companies to further the application of technologies for "out licensing" towards achieving targeted drug delivery for their active new chemical entities,” Dr Mak Jawadekar, PreveCeutical’s chief science officer said in a statement.
PreveCeutical is studying its Sol-gel nose-to-brain drug delivery system and non-addictive pain medication at the University of Queensland in the country.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas